At the news
? NEUTRALIMPACT 1/10 144 filed Oct 30, 2026 at 15:38 ET
Director Jason Aryeh filed a Form 144 notice of intent to sell 202 shares of Ligand Pharmaceuticals common stock, with an estimated market value of approximately $64,738 based on the filing date. The proposed sale is small relative to the company's $6.4B market cap and the director's holdings, and the filing is a routine advance notice of a planned trade.
- Director Jason Aryeh filed Form 144 on 2026-10-30 for a proposed sale of 202 shares of Ligand Pharmaceuticals common stock.
- The estimated value of the proposed sale is $64,738.
- The shares were acquired on 03/13/2019 via an open market purchase.
- The proposed sale is to be executed through Charles Schwab & Co., Inc. on Nasdaq.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access